Scratching the surface-Managing the itch associated with burns: A review of current knowledge

Burns

Volumn 34, Issue 6, 2008, Pages 751-760

  Brooks, J P ^a   Malic, C C ^b   Judkins, K C ^b  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b PINDERFIELDS GENERAL HOSPITAL   (United Kingdom)

Author keywords

Anti itch therapy; Burns; Itch; Nerve transmission; Receptor agonists

Indexed keywords

1 (2 HYDROXYPHENYL) 4 (3 NITROPHENYL) 1,2,3,6 TETRAHYDROPYRIMIDIN 2 ONE; 17 METHYLNALTREXONE; AMINOCAPROIC ACID; ANANDAMIDE; BUTORPHANOL; CAPSAICIN; CHLORPHENIRAMINE; CYPROHEPTADINE; DIPHENHYDRAMINE; DOXEPIN; EMLA; GABAPENTIN; HYDROCORTISONE; HYDROXYZINE; LORATADINE; MENTHOL; MEPYRAMINE MALEATE; METHDILAZINE; MU OPIATE RECEPTOR; PARAFFIN; PHOSPHODIESTERASE IV INHIBITOR; PIMECROLIMUS; PROTEINASE ACTIVATED RECEPTOR 2; RESINIFERATOXIN; SILICONE GEL; SILVER; STEROID; SUBSTANCE P RECEPTOR; TACROLIMUS; VANILLOID RECEPTOR 1;

ABSENCE OF SIDE EFFECTS; ACNE; ANTIINFLAMMATORY ACTIVITY; BEHAVIOR DISORDER; BURN; BURN DRESSING; BURN PATIENT; BURNING SENSATION; CELL PROLIFERATION; CONTACT DERMATITIS; COPING BEHAVIOR; CREAM; CYTOTOXICITY; DISTRESS SYNDROME; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG WITHDRAWAL; FOLLICULITIS; GAUZE DRESSING; HEADACHE; HUMAN; HYPERESTHESIA; HYPNOSIS; LOW DRUG DOSE; LOW LEVEL LASER THERAPY; MASSAGE; MEDICAL ASSESSMENT; MOLECULAR MECHANICS; NERVE FIBER C; NONHUMAN; OAT; PRURITUS; PSYCHOLOGIC ASSESSMENT; RASH; REVIEW; RISK FACTOR; SIDE EFFECT; SKIN ALLERGY; SKIN SENSITIVITY; SKIN TINGLING; TH2 CELL; TRANSCUTANEOUS NERVE STIMULATION;

BURNS; EMOLLIENTS; HISTAMINE ANTAGONISTS; HUMANS; NERVE FIBERS, UNMYELINATED; PRURITUS; TREATMENT OUTCOME;

EID: 47749106849     PISSN: 03054179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.burns.2007.11.015     Document Type: Review

References (61)

1. Vitale M., Fields-Blache C., and Luterman A. Severe itching in the patient with burns. J Burn Care Rehabil 12 (1991) 330-333
2. Willebrand M., Low A., Dyster-Aas J., Kildal M., Andersson G., Ekselius L., et al. Pruritus, personality traits and coping in long-term follow-up of burn-injured patients. Acta Derm Venereol 84 (2004) 375-380
3. Stangier U., Ehlers A., and Gieler U. Predicting long-term outcome in group treatment of atopic dermatitis. Psychother Psychosom 73 (2004) 293-301
4. Field T., Peck M., Hernandez-Reif M., Krugman S., Burman I., and Ozment-Schenck L. Postburn itching, pain, and psychological symptoms are reduced with massage therapy. J Burn Care Rehabil 21 (2000) 189-193
5. Jonsson C.E., Schuldt K., Linder J., Bjornhagen V., and Ekholm J. Rehabilitative, psychiatric, functional and aesthetic problems in patients treated for burn injuries-a preliminary follow-up study. Acta Chir Plast 39 (1997) 3-8
6. Lapsley P. Itching for a solution. [comment]. BMJ 330 (2005) 5
7. Hettrick H.H., O'Brien K., Laznick H., Sanchez J., Gorga D., Nagler W., et al. Effect of transcutaneous electrical nerve stimulation for the management of burn pruritus: a pilot study. J Burn Care Rehabil 25 (2004) 236-240
8. Ko M.C. Veiwpoint. 2. How best to fight that nasty itch-from new insights into the neuroimmunological, neuroendocrine, and neurophysiological bases of pruritus to novel therapeutic approaches. Exp Dermatol 14 (2005) 227-229
9. Yosipovitch G., Greaves M., and Schmelz M. Itch. Lancet 361 (2003) 690-694
10. Schmelz M., Schmidt R., Weidner C., Hilliges M., Torebjork H.E., and Handwerker H.O. Chemical response pattern of different classes of C-nociceptors to pruritogens and algogens. J Neurophysiol 89 (2003) 2441-2448
11. Johanek L.M., Meyer R.A., Hartke T., Hobelmann J.G., Maine D.N., LaMotte R.H., et al. Psychophysical and physiological evidence for parallel afferent pathways mediating the sensation of itch. J Neurosci 27 (2007) 7490-7497
12. Babu R.J., Kikwai L., Jaiani L.T., Kanikkannan N., Armstrong C.A., Ansel J.C., et al. Percutaneous absorption and anti-inflammatory effect of a Substance P receptor antagonist: spantide II. Pharm Res 21 (2004) 108-113
13. Dunnick C.A., Gibran N.S., and Heimbach D.M. Substance P has a role in neurogenic mediation of human burn wound healing. J Burn Care Rehabil 17 (1996) 390-396
14. Rawlingson A., Gerard N.P., and Brain S.D. Interactive contribution of NK(1) and kinin receptors to the acute inflammatory oedema observed in response to noxious heat stimulation: studies in NK(1) receptor knockout mice. Br J Pharmacol 134 (2001) 1805-1813
15. Pinter E., Brown B., Hoult J.R., and Brain S.D. Lack of evidence for tachykinin NK1 receptor-mediated neutrophil accumulation in the rat cutaneous microvasculature by thermal injury. Eur J Pharmacol 369 (1999) 91-98
16. Steinhoff M., and Roostermann D. Veiwpoint. 5. How best to fight that nasty itch-from new insights into the neuroimmunological, neuroendocrine, and neurophysiological bases of pruritus to novel therapeutic approaches. Exp Dermatol 14 (2005) 231-234 [erratum appears in Exp Dermatol 2005;14(June(6)):478-9]
17. Bergasa N.V. Commentary. 7. How best to fight that nasty itch-from new insights into the neuroimmunological, neuroendocrine, and neurophysiological bases of pruritus to novel therapeutic approaches. Exp Dermatol 14 (2005) 237-238 [erratum appears in Exp Dermatol 2005;14(June(6)):478-9]
18. Bigliardi P. Commentary. 4. How best to fight that nasty itch-from new insights into the neuroimmunological, neuroendocrine, and neurophysiological bases of pruritus to novel therapeutic approaches. Exp Dermatol 14 (2005) 236-237 [erratum appears in Exp Dermatol 2005;14(June(6)):478-9]
19. Kamei C., and Hossen M.A. Commentary. 2. How best to fight that nasty itch-from new insights into the neuroimmunological, neuroendocrine, and neurophysiological bases of pruritus to novel therapeutic approaches. Exp Dermatol 14 (2005) 225-240 [erratum appears in Exp Dermatol 2005;14(June(6)):478-9]
20. Biro T., and Szabo T. Viewpoint. 1. How best to fight that nasty itch-from new insights into the neuroimmunological, neuroendocrine, and neurophysiological bases of pruritus to novel therapeutic approaches. Exp Dermatol 14 (2005) 225-227 [erratum appears in Exp Dermatol 2005;14(June(6)):478-9]
21. Biro T., Ko M.C., Bromm B., Wei E.T., Bigliardi P., Siebenhaar F., et al. How best to fight that nasty itch-from new insights into the neuroimmunological, neuroendocrine, and neurophysiological bases of pruritus to novel therapeutic approaches. Exp Dermatol 14 (2005) 225-240 [erratum appears in Exp Dermatol 2005;14(June(6)):478-9]
22. Schmelz M. Veiwpoint. 4. How best to fight that nasty itch-from new insights into the neuroimmunological, neuroendocrine, and neurophysiological bases of pruritus to novel therapeutic approaches. Exp Dermatol 14 (2005) 230-231 [erratum appears in Exp Dermatol 2005;14(June(6)):478-9]
23. Bromm B. Veiwpoint. 3. How best to fight that nasty itch-from new insights into the neuroimmunological, neuroendocrine, and neurophysiological bases of pruritus to novel therapeutic approaches. Exp Dermatol 14 (2005) 229-230 [erratum appears in Exp Dermatol 2005;14(June(6)):478-9]
24. Shimizu S., Tanaka H., Sakaki S., Yukioka T., Matsuda H., and Shimazaki S. Burn depth affects dermal interstitial fluid pressure, free radical production, and serum histamine levels in rats. J Trauma Injury Infect Crit Care 52 (2002) 683-687 [erratum appears in J Trauma 2003;54(April(4)):749]
25. Lindblom L., Cassuto J., Yregard L., Tarnow P., Rantfors J., and Lowhagen Henden P. Role of vasoactive intestinal polypeptide in burn-induced oedema formation. Burns 26 (2000) 443-448
26. Lofgren O., Qi Y., and Lundeberg T. Inhibitory effects of tachykinin receptor antagonists on thermally induced inflammatory reactions in a rat model. Burns 25 (1999) 125-129
27. Santos F.X., Arroyo C., Garcia I., Blasco R., Obispo J.M., Hamann C., et al. Role of mast cells in the pathogenesis of postburn inflammatory response: reactive oxygen species as mast cell stimulators. Burns 26 (2000) 145-147
28. Hebda P., Collins M., and Tharp M. Mast cells and myofibroblasts in wound healing. Dermatol Clin 11 (1993) 685-696
29. 2 antagonists. J Burn Care Rehabil 22 (2001) 263-268
30. Munster A.M., Horowitz G.L., and Tudahl L.A. The abbreviated burn-specific health scale. J Trauma Injury Infect Crit Care 27 (1987) 425-428
31. Herndon D.N. Total burn care (2007), Saunders Elsevier, Philadelphia p. 802
32. Ratcliff S.L., Brown A., Rosenberg L., Rosenberg M., Robert R.S., Cuervo L.J., et al. The effectiveness of a pain and anxiety protocol to treat the acute pediatric burn patient. Burns 32 (2006) 554-562
33. Matheson J.D., Clayton J., and Muller M.J. The reduction of itch during burn wound healing. J Burn Care Rehabil 22 (2001) 76-81
34. Yosipovich G. Assessment of itch: more to be learned and improvements to be made. J Invest Dermatol 121 (2003) 14-15
35. Bringhurst C., Waterstone K., Schofield O., Benjamin K., and Rees J. Measurement of itch using actigraphy in pediatricand adult population. J Am Acad Dermatol 51 (2004) 893-898
36. Mendham J.E. Gabapentin for the treatment of itching produced by burns and wound healing in children: a pilot study. Burns 30 (2004) 851-853
37. Whitaker C. The use of TENS for pruritus relief in the burns patient: an individual case report. J Burn Care Rehabil 22 (2001) 274-276
38. Allison K.P., Kiernan M.N., Waters R.A., and Clement R.M. Pulsed dye laser treatment of burn scars. Alleviation or irritation?. Burns 29 (2003) 207-213
39. Gaida K., Koller R., Isler C., Aytekin O., Al-Awami M., Meissl G., et al. Low level laser therapy-a conservative approach to the burn scar?. Burns 30 (2004) 362-367
40. Barone C.M., Mastropieri C.J., Peebles R., and Mitra A. Evaluation of the Unna Boot for lower-extremity autograft burn wounds excoriated by pruritus in pediatric patients. J Burn Care Rehabil 14 (1993) 348-349
41. Demling R., and De Santi L. Doxepin cream significantly decreases itching and erythema in the healed burn compared to oral antihistamines. J Burn Care Rehabil 23 (2002) s81
42. Groene D., Martus P., and Heyer G. Doxepin affects acetylcholine induced cutaneous reactions in atopic eczema. Exp Dermatol 10 (2001) 110-117
43. Drake L.A., Fallon J.D., and Sober A. Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. The Doxepin Study Group. J Am Acad Dermatol 31 (1994) 613-616
44. Kopecky E.A., Jacobson S., Bch M.B., Hubley P., Palozzi L., Clarke H.M., et al. Safety and pharmacokinetics of EMLA in the treatment of postburn pruritus in pediatric patients: a pilot study. J Burn Care Rehabil 22 (2001) 235-242
45. So K., Umraw N., Scott J., Campbell K., Musgrave M., and Cartotto R. Effects of enhanced patient education on compliance with silicone gel sheeting and burn scar outcome: a randomized prospective study. J Burn Care Rehabil 24 (2003) 411-417
46. Bhol K.C., Alroy J., and Schechter P.J. Anti-inflammatory effect of topical nanocrystalline silver cream on allergic contact dermatitis in a guinea pig model. Clin Exp Dermatol 29 (2004) 282-287
47. Brooks P., Phang K.L., and Moazzam A. Nanocrystalline silver (Acticoat) for itch relief in burns patients. ANZ J Surg 77 (2007) 797
48. Tsipouras N., Rix C.J., and Brady P.H. Passage of silver ions through membrane-mimetic materials, and its relevance to treatment of burn wounds with silver sulfadiazine cream. Clin Chem 43 (1997) 290-301
49. Wagner P.A., Hoekstra W.G., and Ganther H.E. Alleviation of silver toxicity by selenite in the rat in relation to tissue glutathione peroxidase. Proc Soc Exp Biol Med 148 (1975) 1106-1110
50. Hussain S., Anner R.M., and Anner B.M. Cysteine protects Na,K-ATPase and isolated human lymphocytes from silver toxicity. Biochem Biophys Res Commun 189 (1992) 1444-1449
51. Hollinger M.A. Toxicological aspects of topical silver pharmaceuticals. Crit Rev Toxicol 26 (1996) 255-260 [review, 57 refs]
52. Anand P. Capsaicin and menthol in the treatment of itch and pain: recently cloned receptors provide the key. Gut 52 (2003) 1233-1235
53. Hoetzenecker W., Ecker R., Kopp T., Stuetz A., Stingl G., and Elbe-Burger A. Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis. J Allergy Clin Immunol 115 (2005) 1276-1283
54. Simpson D., and Noble S. Tacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions. Drugs 65 (2005) 827-858 [review, 200 refs]
55. Breuer K., Werfel T., and Kapp A. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. Am J Clin Dermatol 6 (2005) 65-77 [review, 97 refs]
56. Coskun B., Saral Y., and Turgut D. Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. Eur J Dermatol 15 (2005) 88-91
57. Rucklidge J., and Saunders D. The efficacy of hypnosis in the treatment of pruritis in people with HIV/AIDS. Int J Clin Exp Hypnosis 50 (2002) 149-169
58. Baumer W., Gorr G., Hoppmann J., Ehinger A.M., Rundfeldt C., and Kietzmann M. AWD 12-281, a highly selective phosphodiesterase 4 inhibitor, is effective in the prevention and treatment of inflammatory reactions in a model of allergic dermatitis. J Pharm Pharmacol 55 (2003) 1107-1114
59. Baumer W., Hoppmann J., Rundfeldt C., and Kietzmann M. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets 6 (2007) 17-26
60. Azrin N.H., and Nunn R.G. Habit reversal: a method of eliminating nervous habits and tics. Behav Res Ther 11 (1973) 619-628
61. Edvinsson E. Pain after severe burn trauma-connections to personality traits and coping, vol. Masters Thesis (2002), Institute for Neurovetenskap, Psykiatri, Uppsala p. 23